Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Portugal / NCT04834869
Recruiting Observational

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869 · tracked via the Priya Life Science Portugal tracker
Sponsor
Masaryk University
Phase
Observational
Started
2021-04-01
Last updated
2022-04-06

Condition(s) studied

Adverse Reaction to VaccineCOVID19 Vaccine

Investigational drug(s) / intervention(s)

BNT162b2 →mRNA-1273 →AZD1222CoronaVacSinopharmGam-COVID-VacJNJ-78436735CVnCoVNVX-CoV2373BBV152

BNT162b2: Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

mRNA-1273: Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

AZD1222: Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)

CoronaVac: Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

Sinopharm: Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

Gam-COVID-Vac: Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

JNJ-78436735: Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

CVnCoV: Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

NVX-CoV2373: Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

BBV152: Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)

Study summary

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * HCW, OA and ST who received COVID-19 vaccine. * Participating subjects should be at least 18-year-old and able to give their informed consent independently. Exclusion Criteria: * Non HCW, OA and ST who received the COVID-19.

Primary outcome measure(s)

Trial sites (14)

FacilityCityRegionStatus
American College of Physicians Philadelphia Pennsylvania Not Yet Recruiting
McMaster University Hamilton Ontario Not Yet Recruiting
University of Split Split Croatia Not Yet Recruiting
Masaryk University Brno Czechia Recruiting
University of Tartu Tartu Estonia Not Yet Recruiting
Jimma University Jimma Ethiopia Recruiting
Justus-Liebig University Giessen Giessen Germany Recruiting
University of Ghana Accra Ghana Not Yet Recruiting
Sinaloa's Pediatric Hospital Culiacán Mexico Not Yet Recruiting
Medical University of Silesia Katowice Poland Recruiting
Nursing School of Coimbra Coimbra Portugal Not Yet Recruiting
Irkutsk Scientific Center of Siberian Branch of Russian Academy of Sciences Irkutsk Russia Recruiting
University of Belgrade Belgrade Serbia Recruiting
University of Ljubljana Ljubljana Slovenia Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04834869 on ClinicalTrials.gov ↗ ← All trials in Portugal